Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 1.00 |
| ▸ | MST1R | Q04912 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | TEK | Q02763 | 4/20 | 1.00 |
| ▸ | BTK | Q06187 | 4/20 | 1.00 |
| ▸ | HGF | P14210 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | FLT4 | P35916 | 3/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 3/20 | 0.77 |
| ▸ | LCK | P06239 | 3/20 | 0.77 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.77 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.77 |
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | CSF1R | P07333 | 2/20 | 0.72 |
| ▸ | AXL | P30530 | 3/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439859 | 1.00 | MET (1.00) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL13511860 | 0.95 | MET (0.91) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2868521 | 0.95 | MET (0.91) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2863129 | 0.95 | MET (0.90) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2869076 | 0.95 | MET (1.00) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2861831 | 0.94 | MET (0.88) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2861036 | 0.89 | MET (0.80) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL3913569 | 0.88 | MET (0.79) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL15405418 | 0.88 | MET (0.79) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2855807 | 0.88 | MET (1.00) | METMST1RKDRRPS6KB1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | claimed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | claimed |
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | MET 563/4885MST1R 413/4885KDR 498/4885 |
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | MET 3/4885MST1R 815/4885KDR 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.